Simultaneous Integrated IMRT Boost for Locally Advanced Gynecological Cancers: Radiobiological and Dosimetric Considerations
M Guerrero,XA Li,L Ma,J Linder,C DeYoung,B Erickson
DOI: https://doi.org/10.1016/j.ijrobp.2004.07.406
2004-01-01
Abstract:Purpose/ObjectiveWhole pelvic irradiation (WPI) followed by a boost to the tumor site is the standard of practice for the radiotherapeutic (RT) management of locally advanced gynecologic cancers. The boost is frequently carried out using intracavitary brachytherapy or occasionally using external beam RT (EBRT) when brachytherapy is not appropriate. The widespread use of EBRT for the boost has been hampered by the problem of target localization and movement. Recently, Low et al1 have proposed the use of applicator-guided IMRT for the boost after the EBRT. To effectively utilize this applicator-guided technology, we propose to use IMRT simultaneous integrated boost (SIB), which is a single-phase process, to replace the conventional two-phase process involving WPI plus an EBRT or a HDR brachytherapy boost. Radiobiological modeling is used to design appropriate regimes for the IMRT SIB. To demonstrate feasibility, a dosimetric study is carried out on sample patients.Materials/MethodsThe standard linear-quadratic (LQ) model is used to calculate the biologically effective dose (BED) and equivalent uniform dose (EUD). Several regimes that are biologically equivalent to conventional two-phase treatments are calculated for the proposed SIB. A commercial inverse planning system (Corvus) was used to generate IMRT SIB plans for sample patient cases using the newly-designed appropriate fractionations. The dose volume histogram (DVH) and EUD of both the target and normal structures for conventional treatments and the SIB are compared.ResultsSeveral appropriate fractionation regimes that are equivalent to the conventional treatments and are suitable for the IMRT SIB are calculated. For example, the SIB plan with 25x3.1Gy (77.5Gy) to tumor site is equivalent to a conventional treatment of EBRT of 45Gy to the whole pelvis plus an HDR brachytherapy boost with 30Gy in 5 fractions. The normal tissue BED is lower for the SIB plan than for the whole pelvis plus HDR scheme, suggesting that the IMRT SIB has a better therapeutic ratio. Three IMRT SIB plans were generated with 25x1.8Gy to the pelvic nodes and 25x2.4(60Gy), 25x2.8Gy(70Gy) and 25x3.2Gy(80Gy) to the tumor site respectively. The target coverage ranged from 94 to 95.5%. The figure below shows the DVH comparison for the rectum and the bladder of the IMRT SIB plans with a whole pelvis(45 Gy) plus HDR treatment of 5x6Gy. The HDR DVHs were obtained from Low et al1 and rescaled for this particular prescription dose. Both the rectum and bladder were assumed to get 45Gy during the whole pelvis treatment. The BED was calculated in each dose-bin and then transformed to the equivalent dose in 1.8Gy per fractions. The sparing of bladder and rectum is significantly improved with the SIB treatment, as compared to the conventional treatments. The proposed SIB treatment can potentially reduce the treatment time to 5 weeks. This is an additional advantage of the SIB schedule, since cervical cancer is known to be a rapidly growing tumor.ConclusionsIt is radiobiologically and dosimetrically feasible to use an IMRT SIB to replace the conventional two-phase treatments (whole pelvic irradiation followed by brachytherapy or EBRT boost) for locally advanced gynecological cancer. In addition to its shorter treatment time, the proposed IMRT SIB can provide significant sparing to normal structures. Purpose/ObjectiveWhole pelvic irradiation (WPI) followed by a boost to the tumor site is the standard of practice for the radiotherapeutic (RT) management of locally advanced gynecologic cancers. The boost is frequently carried out using intracavitary brachytherapy or occasionally using external beam RT (EBRT) when brachytherapy is not appropriate. The widespread use of EBRT for the boost has been hampered by the problem of target localization and movement. Recently, Low et al1 have proposed the use of applicator-guided IMRT for the boost after the EBRT. To effectively utilize this applicator-guided technology, we propose to use IMRT simultaneous integrated boost (SIB), which is a single-phase process, to replace the conventional two-phase process involving WPI plus an EBRT or a HDR brachytherapy boost. Radiobiological modeling is used to design appropriate regimes for the IMRT SIB. To demonstrate feasibility, a dosimetric study is carried out on sample patients. Whole pelvic irradiation (WPI) followed by a boost to the tumor site is the standard of practice for the radiotherapeutic (RT) management of locally advanced gynecologic cancers. The boost is frequently carried out using intracavitary brachytherapy or occasionally using external beam RT (EBRT) when brachytherapy is not appropriate. The widespread use of EBRT for the boost has been hampered by the problem of target localization and movement. Recently, Low et al1 have proposed the use of applicator-guided IMRT for the boost after the EBRT. To effectively utilize this applicator-guided technology, we propose to use IMRT simultaneous integrated boost (SIB), which is a single-phase process, to replace the conventional two-phase process involving WPI plus an EBRT or a HDR brachytherapy boost. Radiobiological modeling is used to design appropriate regimes for the IMRT SIB. To demonstrate feasibility, a dosimetric study is carried out on sample patients. Materials/MethodsThe standard linear-quadratic (LQ) model is used to calculate the biologically effective dose (BED) and equivalent uniform dose (EUD). Several regimes that are biologically equivalent to conventional two-phase treatments are calculated for the proposed SIB. A commercial inverse planning system (Corvus) was used to generate IMRT SIB plans for sample patient cases using the newly-designed appropriate fractionations. The dose volume histogram (DVH) and EUD of both the target and normal structures for conventional treatments and the SIB are compared. The standard linear-quadratic (LQ) model is used to calculate the biologically effective dose (BED) and equivalent uniform dose (EUD). Several regimes that are biologically equivalent to conventional two-phase treatments are calculated for the proposed SIB. A commercial inverse planning system (Corvus) was used to generate IMRT SIB plans for sample patient cases using the newly-designed appropriate fractionations. The dose volume histogram (DVH) and EUD of both the target and normal structures for conventional treatments and the SIB are compared. ResultsSeveral appropriate fractionation regimes that are equivalent to the conventional treatments and are suitable for the IMRT SIB are calculated. For example, the SIB plan with 25x3.1Gy (77.5Gy) to tumor site is equivalent to a conventional treatment of EBRT of 45Gy to the whole pelvis plus an HDR brachytherapy boost with 30Gy in 5 fractions. The normal tissue BED is lower for the SIB plan than for the whole pelvis plus HDR scheme, suggesting that the IMRT SIB has a better therapeutic ratio. Three IMRT SIB plans were generated with 25x1.8Gy to the pelvic nodes and 25x2.4(60Gy), 25x2.8Gy(70Gy) and 25x3.2Gy(80Gy) to the tumor site respectively. The target coverage ranged from 94 to 95.5%. The figure below shows the DVH comparison for the rectum and the bladder of the IMRT SIB plans with a whole pelvis(45 Gy) plus HDR treatment of 5x6Gy. The HDR DVHs were obtained from Low et al1 and rescaled for this particular prescription dose. Both the rectum and bladder were assumed to get 45Gy during the whole pelvis treatment. The BED was calculated in each dose-bin and then transformed to the equivalent dose in 1.8Gy per fractions. The sparing of bladder and rectum is significantly improved with the SIB treatment, as compared to the conventional treatments. The proposed SIB treatment can potentially reduce the treatment time to 5 weeks. This is an additional advantage of the SIB schedule, since cervical cancer is known to be a rapidly growing tumor. Several appropriate fractionation regimes that are equivalent to the conventional treatments and are suitable for the IMRT SIB are calculated. For example, the SIB plan with 25x3.1Gy (77.5Gy) to tumor site is equivalent to a conventional treatment of EBRT of 45Gy to the whole pelvis plus an HDR brachytherapy boost with 30Gy in 5 fractions. The normal tissue BED is lower for the SIB plan than for the whole pelvis plus HDR scheme, suggesting that the IMRT SIB has a better therapeutic ratio. Three IMRT SIB plans were generated with 25x1.8Gy to the pelvic nodes and 25x2.4(60Gy), 25x2.8Gy(70Gy) and 25x3.2Gy(80Gy) to the tumor site respectively. The target coverage ranged from 94 to 95.5%. The figure below shows the DVH comparison for the rectum and the bladder of the IMRT SIB plans with a whole pelvis(45 Gy) plus HDR treatment of 5x6Gy. The HDR DVHs were obtained from Low et al1 and rescaled for this particular prescription dose. Both the rectum and bladder were assumed to get 45Gy during the whole pelvis treatment. The BED was calculated in each dose-bin and then transformed to the equivalent dose in 1.8Gy per fractions. The sparing of bladder and rectum is significantly improved with the SIB treatment, as compared to the conventional treatments. The proposed SIB treatment can potentially reduce the treatment time to 5 weeks. This is an additional advantage of the SIB schedule, since cervical cancer is known to be a rapidly growing tumor. ConclusionsIt is radiobiologically and dosimetrically feasible to use an IMRT SIB to replace the conventional two-phase treatments (whole pelvic irradiation followed by brachytherapy or EBRT boost) for locally advanced gynecological cancer. In addition to its shorter treatment time, the proposed IMRT SIB can provide significant sparing to normal structures. It is radiobiologically and dosimetrically feasible to use an IMRT SIB to replace the conventional two-phase treatments (whole pelvic irradiation followed by brachytherapy or EBRT boost) for locally advanced gynecological cancer. In addition to its shorter treatment time, the proposed IMRT SIB can provide significant sparing to normal structures.